可利霉素对口腔鳞癌细胞生物学活性的影响

目的: 体外评价可利霉素对口腔鳞状细胞癌的抗肿瘤活性。方法: 梯度浓度可利霉素分别处理口腔鳞状细胞癌细胞（HN6/HB96细胞系）,采用CCK-8试剂盒检测细胞增殖,绘制生长曲线;采用划痕实验分析细胞迁移能力;采用平板克隆形成实验分析细胞克隆形成能力;采用流式细胞术分析细胞周期和细胞凋亡。采用 SPSS 18.0 软件包对数据进行统计学分析。结果: 可利霉素浓度依赖性抑制HN6/HB96的体外增殖,随着药物浓度增加,细胞迁移和克隆形成能力显著下降（P<0.05）;可利霉素使处理过的口腔鳞状细胞癌细胞G1期比例显著升高,S期和G2/M期比例显著下降,细胞周期阻滞于G1期（P<0.001）。可利霉素诱导口腔鳞状细胞癌细胞凋亡,随着药物浓度增加,细胞凋亡率显著上升（P<0.01）。结论: 可利霉素体外抑制口腔鳞状细胞癌细胞的生物学活性,为可利霉素用于口腔鳞状细胞癌的治疗提供了实验依据。

Inhibitory effect of carrimycin on biological activity of oral squamous cell carcinoma cells in vitro

PURPOSE: As a new macrolide antibiotic with independent intellectual property rights of China, carrimycin not only has good antibacterial effect on a variety of bacteria, but also has the function of regulating cell physiology and proliferation.The aim of this study was to investigate the anti-tumor effects of carrimycin on the biological activity of oral squamous cell carcinoma (OSCC) cells in vitro. METHODS: OSCC cells (HN6/HB96 cell lines) were treated with gradient concentration of carrimycin. Cell proliferation was detected using CCK-8 kit, based on which cell growth curve was drawn. Cell migration ability was analyzed by wound-healing assay. Cell clone formation ability was analyzed by clone formation assay. Cell cycle and apoptosis were analyzed by flow cytometry. SPSS18.0 software package was used for statistical analysis. RESULTS: Carrimycin concentration-dependently inhibited cellular proliferation of OSCC cells of HN6 and HB96 in vitro. With the increase of drug concentration, cell migration and clonal formation ability significantly decreased (P<0.05). The G1 phase ratio of OSCC cells treated with carrimycin significantly increased, while the S and G2/M phase ratio decreased, indicating that the cell cycle was arrested in G1 phase(P<0.001). The apoptosis rate of OSCC cells was significantly increased with the increase of drug concentration (P<0.01). CONCLUSIONS: The activity of OSCC cells can be effectively inhibited by carrimycin, which provides experimental evidence for the application of carrimycin in OSCC.